Find Academic Supervisors

Dr. Miguel Ganuza serves as a Senior Lecturer and Group Leader at Queen Mary University of London's Centre for Haemato-Oncology, where he investigates fundamental mechanisms of haematopoietic stem cell function and their subversion in leukaemia. His academic foundation includes a BSc, MSc, and PhD, supporting his expertise in stem cell biology and cancer research. His research spans critical themes including Cancer and Ageing, Cancer Cell Biology, Stem Cells, Tumour Microenvironment, Leukaemia, and Haematopoiesis. Dr. Ganuza's work integrates developmental biology with translational cancer research to dissect clonal evolution, stem cell exhaustion, and niche interactions in blood disorders. His publication record reveals a consistent trajectory in murine hematopoiesis research, focusing on stem cell ontogeny, clonal dynamics during aging, and genetic regulation of stem cell maintenance. Key contributions include elucidating embryonic origins of hematopoietic stem cells and mechanisms linking cell cycle regulation to premature aging. Dr. Ganuza's scientific excellence is recognized through prestigious awards: American Society of Hematology (ASH) Global Research Award (2021) Medical Research Council Career Development Award (2021-2025) Leukaemia UK John Goldman Fellowship (2020-2022) He directs a research program supported by major grants from The Kay Kendall Leukaemia Fund (£137,792), ASH ($150,000), MRC (£1.5M), Leukaemia UK (£123,856), and Barts Charity, focusing on bone marrow niche identification and clonal haematopoiesis pathways. As Group Leader, he mentors a multidisciplinary team within the Centre for Haemato-Oncology. His laboratory employs advanced genetic engineering and stem cell transplantation techniques to model leukemogenesis and dissect stem cell-niche interactions, positioning his research at the intersection of basic science and therapeutic development for blood cancers.

• Cancer and Ageing
• Cancer Cell Biology
• Stem Cells
• +3 more

Dr. Sergey Krysov serves as Reader in Molecular Biology and Group Leader at the Barts Cancer Institute, Queen Mary University of London. He holds the position of Director of Undergraduate Studies for the institute and is an active member of the European Research Initiative on CLL (ERIC). His academic role encompasses research leadership, undergraduate program oversight, and specialized teaching in hemato-oncology. Dr. Krysov's research centers on immunogenetics of B-cell malignancies, with primary focus on chronic lymphocytic leukemia (CLL) and follicular lymphoma. He investigates B-cell receptor (BCR) signaling pathways, immunoglobulin glycosylation patterns, and tumor microenvironment interactions. His work spans cancer prevention mechanisms, targeted tumor cell therapies, and cell signaling dysregulation, with particular emphasis on how acquired N-glycosylation sites drive lymphoma evolution and how lectin binding triggers persistent BCR activation. Analysis of his 15 most recent publications (2014-2025) reveals consistent thematic focus on BCR signaling abnormalities in CLL and follicular lymphoma. Key research trajectories include CD180 expression patterns across anatomical compartments, EMT-like activation as a therapeutic target, metabolic reprogramming through glycolysis enhancement, and microbiome interactions via bacterial lectins. His work demonstrates translational potential through identification of novel biomarkers and therapeutic vulnerabilities. Scientific recognition includes: John Goldman Fellowship for Future Science (Leuka, 2016-2018) Dr. Krysov has secured substantial research funding including a Barts Charity Strategic Research Grant (2016-2020, £77,487) investigating peripheral blood composition in CLL patients, a Leuka fellowship (2016-2018, £100,000) studying the BCR-ZEB2 axis, and current Barts Charity project (2021-2024, £256,000) examining EMT-like activation in B-cell malignancies. He leads teaching modules BMD211 Human Molecular Biology and CANM935 Molecular Targeted Therapies for Blood Cancers. As Group Leader within the Centre for Haemato-Oncology Research, he directs a multidisciplinary team utilizing genomic sequencing, primary patient samples, and xenograft models to dissect molecular mechanisms of B-cell malignancies, with current emphasis on therapeutic targeting of EMT-like pathways and microbiome-BCR interactions.

• Immunogenetics
• B cell malignancies
• Chronic Lymphocytic Leukemia
• +5 more

Joash Joy is a Postdoctoral Researcher affiliated with the Centre for Tumour Microenvironment . His research focuses on developing human tumour models within microfluidic chips to study the tumour microenvironment, particularly blood vessels, and evaluating the delivery and efficacy of genetically modified immune cells in targeting cancer cells. Research Interests : 3D Modelling Immunotherapy Tumour Microenvironment Ovarian Cancer

• 3D Modelling
• Immunotherapy
• Tumour Microenvironment
• +1 more

Barrie Peck is a Senior Lecturer and Group Leader at the Centre for Tumour Biology. His research focuses on understanding how cancer metabolism alters under extrinsic influences like diet and the tumor microenvironment, with a particular emphasis on therapeutic exploitation of these metabolic dependencies. Key research themes include: Cancer Cell Biology Metabolism Tumour Microenvironment 3D Modelling Disease-specific interests span breast cancer, glioma, and lung cancer. His work has been funded by Barts Charity and Cancer Research UK, including a £1.1M CRUK Career Establishment Award. Professional affiliations include: Member of the British Association for Cancer Research Member of the European Association for Cancer Research Committee member for Breast Cancer Now grants

• 3D Modelling
• Cancer Cell Biology
• Metabolism
• +4 more

Kevin Rouault-Pierre serves as a Reader (equivalent to Associate Professor) in Stem Cell Biology at Queen Mary University of London's Centre for Haemato-Oncology, where he leads a research group investigating hematopoietic stem cells and leukemic initiating cells. His work focuses on signal integration in normal and malignant stem cells within blood disorders. Education: Bachelor of Science (BSc) Master of Science (MSc) Doctor of Philosophy (PhD) His research centers on myelodysplastic syndromes (MDS) and leukemia pathogenesis, examining how intrinsic factors like SF3B1 mutations and extrinsic elements such as metabolic alterations disrupt erythropoiesis and reshape bone marrow microenvironments. Key themes include Cell Signalling, Disease Modelling, and Metabolism in cancer contexts, with particular emphasis on targeting tumour cells through metabolic interventions. His group employs preclinical models to bridge basic mechanisms with therapeutic applications. Analysis of his 2013-2023 publications reveals consistent translational focus: metabolic pathways (Vitamin B5/succinyl-CoA) for ineffective erythropoiesis, DNA repair defects (ERCC6L2), and splicing factor mutations (SF3B1) in MDS. His work demonstrates progression from foundational stem cell biology (2013-2016) toward targeted metabolic therapies (2022-2023), highlighting evolving strategies to modulate the bone marrow microenvironment. No scientific awards are documented in the source material. He secures significant funding including CRUK Early Detection Awards (2023-2026), Barts Charity Project Grants (2022-2025), and European Hematology Association Collaborative Grants (2024-2025). While specific students aren't listed, his Group Leader role implies active mentorship of researchers within his laboratory. His team operates within Queen Mary's Centre for Haemato-Oncology, collaborating through memberships in the British Society of Haematology, European Haematology Association, and Société Française d'Hématologie to advance translational research in blood cancers.

• Stem Cell Biology
• Leukemia
• Hematopoiesis
• +3 more

Dr. Caroline Hill is a Principal Group Leader and Assistant Research Director at The Francis Crick Institute in London, UK, where she heads the Developmental Signalling Laboratory. She received her PhD from the University of Cambridge in 1989 and completed postdoctoral work at the Imperial Cancer Research Fund before establishing her independent research career. Her research focuses on cellular communication mechanisms, particularly the Transforming Growth Factor β (TGF-β) superfamily of signaling molecules, which play critical roles in early embryonic development and cancer progression. Dr. Hill's laboratory employs diverse approaches including zebrafish models, cell culture systems, and computational modeling to understand how these signaling pathways function and how their dysregulation contributes to disease. Her publication record demonstrates consistent high-impact research in developmental biology and signaling, with particular emphasis on NODAL and BMP signaling pathways, morphogen gradient formation, and the molecular mechanisms of TGF-β superfamily receptor activation. Her work bridges fundamental biological mechanisms with potential therapeutic applications in cancer treatment. EMBO membership (2002) Academia Europaea membership (2013) European Academy of Cancer Sciences membership (2015) Royal Society University Research Fellowship (1995) Dr. Hill's research program has evolved from fundamental studies of TGF-β signaling mechanisms to increasingly translational work examining how these pathways can be targeted for cancer therapy, as evidenced by her recent publications exploring therapeutic interventions in tumor models.

• Cell Biology
• Developmental Biology
• Signalling & Oncogenes
• +5 more

Professor Katy Mason is PVC Dean at the University of Salford's Salford Business School and President of the British Academy of Management. With a distinguished career spanning multiple prestigious institutions, she has established herself as a leading scholar in market studies and moral markets research. Her work focuses on collaborative innovation systems designed to co-create markets that benefit people and the planet while respecting planetary boundaries. Her research interests include Ethnography, Management Practices, Market Studies, Moral Markets, Practice Theory, and Sustainable Business. Professor Mason has published extensively in top journals including Journal of Management Studies, Organization Studies, and British Journal of Management, with 45 research outputs spanning from 2012 to 2025. Her recent work explores digital methodologies, cyber-physical marketization, and the role of universities in addressing climate change. Professor Mason's publications reveal a consistent focus on how markets are made, shaped, and transformed through collaborative processes. Her work spans diverse contexts from electric vehicle infrastructure to rural 5G implementation, always with an eye toward creating markets that generate social, environmental and economic value. She has made significant contributions to understanding market infrastructures, market-referencing practices, and the institutional work required to operate in subsistence marketplaces. Fellow of the British Academy of Management (FBAM) Fellow of the Academy of Social Science (FAcSS) Chartered Companion of the Chartered Management Institute (CCMI) Cabinet Office Policy Fellow As an academic leader, Professor Mason has served as Associate Dean for Research at Lancaster University Management School and currently as PVC Dean at the University of Salford. She contributes to multiple editorial boards including Management Learning, Industrial Marketing Management, Journal of Management Studies, and the British Journal of Management. Her leadership extends to policy impact, where she explores how business schools can create 'Paradox Boxes' to facilitate academic-policy interactions that address societal challenges. Professor Mason leads research that directly contributes to multiple UN Sustainable Development Goals, particularly those related to quality education, gender equality, sustainable economic growth, innovation, sustainable cities, responsible consumption, and global partnerships. Her current work with organizations like Rolls-Royce, Microsoft, and government bodies demonstrates the practical impact of her theoretical contributions to market studies.

• Market Studies
• Moral Markets
• Ethnography
• +5 more

Lorenzo Ressel serves as Lecturer in Veterinary Pathology at the University of Liverpool, where he has been a core faculty member since 2011. A diplomate of the European College of Veterinary Pathologists (DipECVP) since 2015 and Fellow of the Higher Education Academy (FHEA), he directs the Immunohistochemistry and Electron Microscopy Services while teaching anatomic pathology with emphasis on neoplasia. His educational foundation includes a veterinary degree (2005) and PhD (2009) from the University of Pisa, where his dissertation explored PTEN protein expression in canine and feline mammary tumours. This early work established his expertise in comparative tumour biology that continues to inform his research. Professor Ressel's research spans veterinary pathology with dual emphases: traditional diagnostic pathology (particularly immunohistochemistry for tumour grading) and cutting-edge computational approaches. His recent publications reveal a strategic pivot toward integrating artificial intelligence and natural language processing into veterinary diagnostics, while maintaining active work in forensic pathology and regenerative medicine. This interdisciplinary focus positions him at the forefront of digital transformation in veterinary medicine. Analysis of his 2025 publications shows strong momentum in AI applications, with multiple papers establishing methodological frameworks for computational pathology. His work bridges species-specific veterinary challenges with broader diagnostic innovation, particularly in image analysis standardization and 3D visualization techniques for both educational and diagnostic purposes. Eusropean Society of Veterinary Pathology (ESVP) Oral presentation Award (2013) European Society of Veterinary Oncology (ESVONC) Junior Research Award (2009) Professor Ressel actively supervises postgraduate research through multiple funded projects including Kidney Research UK studies on regenerative therapies and Horserace Betting Levy Board investigations into equine pulmonary diseases. His grant portfolio demonstrates successful translation of basic research into clinical applications, with particular strength in securing competitive European and UK funding. The Immunohistochemistry Service he developed serves as a critical nexus between diagnostic practice and research innovation. As head of the Immunohistochemistry and Electron Microscopy Services, Professor Ressel oversees integrated diagnostic and research operations that handle hundreds of cases annually. These services provide the foundation for his methodological innovations while supporting the University of Liverpool's veterinary hospital and research community, creating a dynamic environment where diagnostic challenges directly inform research priorities.

• Veterinary Pathology
• Tumour Biology
• Immunohistochemistry
• +5 more

Dr. Fabio Simoes is an Assistant Professor in Cancer Research within the Clinical and Experimental Medicine department at Brighton and Sussex Medical School (BSMS), part of the University of Sussex. With over a decade of experience in disease modeling and molecular biology, he leads a research laboratory focused on acute myeloid leukaemia (AML) and the bone marrow microenvironment. Dr. Simoes completed his PhD at BSMS in 2017, following earlier degrees including an MSc in Neuroscience from King's College London and a BSc in Biomedical Sciences from Queen Mary University of London. His research journey began with motor neuron disease studies, progressed through osteoarthritis research, and has now focused on hematological malignancies. His current research examines how AML cells remodel the bone marrow microenvironment to promote disease progression and therapy resistance. By employing in vitro co-culture systems, RNA sequencing, and translational in vivo models, his work aims to identify novel therapeutic targets such as CD44 and Focal Adhesion Kinase to overcome cell adhesion-mediated drug resistance. Analysis of his recent publications reveals a strong focus on tumor microenvironment interactions, computational modeling of blood cancers, and translational approaches to improve treatment outcomes. Dr. Simoes currently holds an active research grant from the SUSSEX CANCER FUND FOR TREATMENT AND RESEARCH (2024-2028) focused on characterizing and targeting chemo-resistant AML cells. His laboratory team includes researchers like Sophie Vause and Aleksandra, who joined in late 2024. As an educator, Dr. Simoes serves as an Academic Skills Tutor, delivers Molecular Cell Biology tutorials, and has designed advanced neuroscience workshops for postgraduate students. He supervises multiple research projects and holds Associate Fellowship of the Higher Education Academy. His laboratory, accessible through www.simoes.science, represents a growing research group dedicated to advancing our understanding of AML biology and developing novel therapeutic approaches that target the tumor microenvironment.

• Acute myeloid leukaemia (AML)
• Bone marrow microenvironment
• Molecular pathology
• +4 more